Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia
Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This study is a phase III, multicenter, randomized, double-blind, active-controlled,
non-inferiority trial designed to assess the efficacy and safety of Brexpiprazole in the
Treatment of Adults With Acute Schizophrenia. A total of approximately 370 subjects will be
included in the study, and randomized to Brexpiprazole (2~4 mg/d) or Aripiprazole (10~20
mg/d) in a 1:1 ratio.